Onchilles Pharma, a private biotech company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway, today announced the publication of foundational preclinical data in Cell ...
The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&GreenCNS ...
Triple-negative breast cancer is one of the most aggressive and difficult cancers to treat. It can initially respond well to ...
The DESTINY-Breast11 trial showed in patients with high-risk HER2-positive early breast cancer that the ADC followed by ...
Neoadjuvant therapy (NAT) for early breast cancer was first introduced in the 1980s to downstage large, inoperable tumors, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback